About PAREXEL
Parexel is an American contract research organization. It conducts clinical trials on behalf of its pharmaceutical and biotechnology clients to expedite drug development and clinical trial progress.
Parexel was founded in 1982 by Josef von Rickenbach and organic chemist Anne B. Sayigh initially to advise Japanese and German firms on how to navigate the US Food and Drug Administration (FDA) drug approval process. The firm has grown organically over the years and through 40 acquisitions. Josef von Rickenbach is credited with establishing Parexel's culture and practices based on the principles he experienced as a researcher at Schering-Plough in Lucerne, Switzerland, before leaving the company upon retiring in 2018. In 1990, the firm expanded internationally and established new practice areas. By 1999, it had a staff of 4,500 and 45 offices.
The company was acquired in 2017 by private equity firm Pamplona Capital Management. On July 2, 2021, Parexel announced a merger agreement under which it would be acquired by EQT IX fund and Goldman Sachs for $8.5 billion. EQT and Goldman Sachs completed the acquisition on November 15, 2021.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
PAREXEL timeline
- 1982
- 🏁· approximateFounded
- 2012
- •Legal Entity Identifier issuedLEI 549300GCZVUYB6P2OA17 registered.
- 2022
- ✎Renamed Parexel International (Ma) CorporationLegal name change recorded in the LEI register.
Events of PAREXEL from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about PAREXEL
- Acquisitions and changes
- No longer listed: ticker PRXL is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
Not enough history yet.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | · | · | · | 3 | · | · | · | · | · | · | · | · | 3 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| effective | 3 people | ClosureWARN notice | San Diego County, California | Notice list |
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| PAREXEL🇺🇸 | — | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- UnitedHealth Group Incorporated$367.7 B
- Merck & Co., Inc.$359.8 B
How current the figures are
- Profile updated:
- Nov 14, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at PAREXEL? Verify and update this profile — free
Show PAREXEL's ranking on your website Get the badge
The badge updates itself as the ranking changes.